CRISPR Therapeutics AG

As of June 30, 2026, CRISPR Therapeutics AG carries a market capitalization of 5.34B, placing it among publicly traded companies globally. Its enterprise value stands at 3.76B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

CRISPR Therapeutics AG's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, CRISPR Therapeutics AG has 96.66M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 476.34, and the price-to-book ratio stands at 3.06.

These figures are as of June 30, 2026. The EV/Sales ratio of 342.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.76B versus a market cap of 5.34B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, CRISPR Therapeutics AG maintains a current ratio of 17.85, meaning it holds 17.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG posted a negative return on equity (ROE) of -26.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.28, reflecting losses generated across the asset base. The company generates approximately 27,989.82 in revenue per employee across its workforce of 393.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG recorded 3.03M in income tax expense. The company reported a pretax loss of -448.11M and -451.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, CRISPR Therapeutics AG's stock has declined approximately 23.66% over the past 52 weeks. The 50-day moving average sits at 54.57, while the 200-day moving average is 53.02.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG generated 11.00M in revenue and converted that into -451.14M in net income, yielding earnings per share of -4.76. EBITDA reached -515.65M, while operating income came in at -534.34M.

As of June 30, 2026, CRISPR Therapeutics AG holds 2.36B in cash and equivalents against 783.75M in total debt, resulting in a net debt position of 294.86M. Total book value stands at 1.75B, with working capital of 2.24B providing operational flexibility.

CRISPR Therapeutics AG produced -369.58M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.74M in capital expenditures, free cash flow totaled -371.32M - equivalent to -3.92 per share.

Over the twelve months ended June 30, 2026, CRISPR Therapeutics AG posted a gross margin of -1,691.26, reflecting its pricing power and cost economics. The operating margin of -4,857.64 and net profit margin of -4,101.26 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.94, meaning CRISPR Therapeutics AG raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, CRISPR Therapeutics AG has an Altman Z-Score of 2.76, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.